154 related articles for article (PubMed ID: 22492392)
21. [Combined FDG PET/CT imaging for restaging of colorectal cancer patients: impact of image fusion on staging accuracy].
Strunk H; Bucerius J; Jaeger U; Joe A; Flacke S; Reinhardt M; Hortling N; Palmedo H
Rofo; 2005 Sep; 177(9):1235-41. PubMed ID: 16123869
[TBL] [Abstract][Full Text] [Related]
22. Imaging features of colorectal liver metastasis in FDG PET-CT: a retrospective correlative analysis between CT attenuation and FDG uptake.
Au-Yeung AW; Luk WH; Lo AX
Nucl Med Commun; 2012 Apr; 33(4):403-7. PubMed ID: 22273638
[TBL] [Abstract][Full Text] [Related]
23. [Value of (18)F-FDG PET-CT in the preoperative N staging of non-small cell lung cancer].
Li M; Wu N; Liang Y; Zheng R; Liu Y; Zhang WJ; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):288-92. PubMed ID: 19615286
[TBL] [Abstract][Full Text] [Related]
24. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
25. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
26. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
[TBL] [Abstract][Full Text] [Related]
27. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
[TBL] [Abstract][Full Text] [Related]
28. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
[TBL] [Abstract][Full Text] [Related]
29. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.
Kantorová I; Lipská L; Bêlohlávek O; Visokai V; Trubaĉ M; Schneiderová M
J Nucl Med; 2003 Nov; 44(11):1784-8. PubMed ID: 14602860
[TBL] [Abstract][Full Text] [Related]
30. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
[TBL] [Abstract][Full Text] [Related]
31. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer.
Shyn PB; Madan R; Wu C; Erturk SM; Silverman SG
AJR Am J Roentgenol; 2010 Feb; 194(2):414-21. PubMed ID: 20093604
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
33. The added value of dual-time-point 18F-FDG PET/CT imaging in the diagnosis of colorectal cancer liver metastases.
Mao W; Zhou J; Qiu L; Yin H; Tan H; Shi H
Abdom Radiol (NY); 2020 Apr; 45(4):1075-1081. PubMed ID: 31927618
[TBL] [Abstract][Full Text] [Related]
34. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
[TBL] [Abstract][Full Text] [Related]
35. Limited Identification of Dual-time-point Positron Emission Tomography/Computed Tomography in Advanced Colorectal Neoplasms.
Kashiwagi K; Nakazato Y; Arai M; Iwasaki E; Naganuma M; Inoue N; Iwao Y; Ogata H; Murakami K; Kanai T
Intern Med; 2017; 56(11):1287-1292. PubMed ID: 28566588
[TBL] [Abstract][Full Text] [Related]
36. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
[TBL] [Abstract][Full Text] [Related]
37. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
38. The potential usefulness of (18)F-FDG PET/CT for detecting colorectal carcinoma and adenoma in asymptomatic adults.
Hwang JP; Woo SK; Yoon SY; Jeong SY
Ann Nucl Med; 2015 Feb; 29(2):157-63. PubMed ID: 25358843
[TBL] [Abstract][Full Text] [Related]
39. What approach should we take for the incidental finding of increased 18F-FDG uptake foci in the colon on PET/CT?
Şimşek FS; İspiroğlu M; Taşdemir B; Köroğlu R; Ünal K; Özercan IH; Entok E; Kuşlu D; Karabulut K
Nucl Med Commun; 2015 Dec; 36(12):1195-201. PubMed ID: 26426964
[TBL] [Abstract][Full Text] [Related]
40. High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging.
Panagiotidis E; Datseris IE; Exarhos D; Skilakaki M; Skoura E; Bamias A
Nucl Med Commun; 2012 Apr; 33(4):431-8. PubMed ID: 22293498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
